385 research outputs found
Capillary Filling of Anodized Alumina Nanopore Arrays
The filling behavior of a room temperature solvent,
perfluoromethylcyclohexane, in approximately 20 nm nanoporous alumina membranes
was investigated in situ with small angle x-ray scattering. Adsorption in the
pores was controlled reversibly by varying the chemical potential between the
sample and a liquid reservoir via a thermal offset, T. The system
exhibited a pronounced hysteretic capillary filling transition as liquid was
condensed into the nanopores. These results are compared with Kelvin-Cohan
theory, with a modified Derjaguin approximation, as well as with predictions by
Cole and Saam.Comment: 4 pages, 3 figures, pre-proof
A descriptive survey of types, spread and characteristics of substance abuse treatment centers in Nigeria
<p>Abstract</p> <p>Background</p> <p>Nigeria, the most populous country in Africa and the 8th most populous in the world with a population of over 154 million, does not have current data on substance abuse treatment demand and treatment facilities; however, the country has the highest one-year prevalence rate of Cannabis use (14.3%) in Africa and ranks third in Africa with respect to the one-year prevalence rate of cocaine (0.7%) and Opioids (0.7%) use. This study aimed to determine the types, spread and characteristics of the substance abuse treatment centers in Nigeria.</p> <p>Methods</p> <p>The study was a cross sectional survey of substance abuse treatment centers in Nigeria. Thirty-one units were invited and participated in filling an online questionnaire, adapted from the European <it>Treatment Unit/Program Form (June 1997 version)</it>.</p> <p>Results</p> <p>All the units completed the online questionnaire. A large proportion (48%) was located in the South-West geopolitical zone of the country. Most (58%) were run by Non-Governmental Organizations. Half of them performed internal or external evaluation of treatment process or outcome. There were a total of 1043 for all categories of paid and volunteer staff, with an average of 33 staff per unit. Most of the funding came from charitable donations (30%). No unit provided drug substitution/maintenance therapy. The units had a total residential capacity of 566 beds. New client admissions in the past one year totalled 765 (mean = 48, median = 26.5, min = 0, max = 147) and 2478 clients received services in the non-residential units in the past year. No unit provided syringe exchange services.</p> <p>Conclusions</p> <p>The study revealed a dearth of substance abuse treatment units (and of funds for the available ones) in a country with a large population size and one of the highest prevalence rates of substance abuse in Africa. The available units were not networked and lacked a directory or an evaluation framework. To provide an environment for effective monitoring, funding and continuous quality improvement, the units need to be organized into a sustainable network.</p
Decision Support for Diabetes in Scotland:Implementation and Evaluation of a Clinical Decision Support System
Background: Automated clinical decision support systems (CDSS) are associated with improvements in health care delivery to those with long-term conditions, including diabetes. A CDSS was introduced to two Scottish regions (combined diabetes population ~30 000) via a national diabetes electronic health record. This study aims to describe users’ reactions to the CDSS and to quantify impact on clinical processes and outcomes over two improvement cycles: December 2013 to February 2014 and August 2014 to November 2014. Methods: Feedback was sought via patient questionnaires, health care professional (HCP) focus groups, and questionnaires. Multivariable regression was used to analyze HCP SCI-Diabetes usage (with respect to CDSS message presence/absence) and case-control comparison of clinical processes/outcomes. Cases were patients whose HCP received a CDSS messages during the study period. Closely matched controls were selected from regions outside the study, following similar clinical practice (without CDSS). Clinical process measures were screening rates for diabetes-related complications. Clinical outcomes included HbA1c at 1 year. Results: The CDSS had no adverse impact on consultations. HCPs were generally positive toward CDSS and used it within normal clinical workflow. CDSS messages were generated for 5692 cases, matched to 10 667 controls. Following clinic, the probability of patients being appropriately screened for complications more than doubled for most measures. Mean HbA1c improved in cases and controls but more so in cases (–2.3 mmol/mol [–0.2%] versus –1.1 [–0.1%], P = .003). Discussion and Conclusions: The CDSS was well received; associated with improved efficiencies in working practices; and large improvements in guideline adherence. These evidence-based, early interventions can significantly reduce costly and devastating complications. </jats:sec
The effect of volume change and stack pressure on solid‐state battery cathodes
Solid-state lithium batteries may provide increased energy density and improved safety compared with Li-ion technology. However, in a solid-state composite cathode, mechanical degradation due to repeated cathode volume changes during cycling may occur, which may be partially mitigated by applying a significant, but often impractical, uniaxial stack pressure. Herein, we compare the behavior of composite electrodes based on Li4Ti5O12 (LTO) (negligible volume change) and Nb2O5 (+4% expansion) cycled at different stack pressures. The initial LTO capacity and retention are not affected by pressure but for Nb2O5, they are significantly lower when a stack pressure of <2 MPa is applied, due to inter-particle cracking and solid-solid contact loss because of cyclic volume changes. This work confirms the importance of cathode mechanical stability and the stack pressures for long-term cyclability for solid-state batteries. This suggests that low volume-change cathode materials or a proper buffer layer are required for solid-state batteries, especially at low stack pressures
Functional Association of Gdown1 with RNA Polymerase II Poised on Human Genes
Most human genes are loaded with promoter-proximally paused RNA polymerase II (Pol II) molecules that are poised for release into productive elongation by P-TEFb. We present evidence that Gdown1, the product of the POLR2M gene that renders Pol II responsive to Mediator, is involved in Pol II elongation control. During in vitro transcription, Gdown1 specifically blocked elongation stimulation by TFIIF, inhibited the termination activity of TTF2, and influenced pausing factors NELF and DSIF, but did not affect the function of TFIIS or the mRNA capping enzyme. Without P-TEFb, Gdown1 led to the production of stably paused polymerases in the presence of nuclear extract. Supporting these mechanistic insights, ChIP-Seq demonstrated that Gdown1 mapped over essentially all poised polymerases across the human genome. Our results establish that Gdown1 stabilizes poised polymerases while maintaining their responsiveness to P-TEFb and suggest that Mediator overcomes a Gdown1-mediated block of initiation by allowing TFIIF function.National Human Genome Research Institute (U.S.) (Grant HG002668-05
Randomized double-blind trial of pregabalin versus placebo in conjunction with palliative radiotherapy for cancer-induced bone pain
Purpose
Cancer-induced bone pain (CIBP) affects one third of patients with cancer. Radiotherapy remains the gold-standard treatment; however, laboratory and clinical work suggest that pregabalin may be useful in treating CIBP. The aim of this study was to examine pregabalin in patients with CIBP receiving radiotherapy.
Patients and Methods
A multicenter, double-blind randomized trial of pregabalin versus placebo was conducted. Eligible patients were age ≥ 18 years, had radiologically proven bone metastases, were scheduled to receive radiotherapy, and had pain scores ≥ 4 of 10 (on 0-to-10 numeric rating scale). Before radiotherapy, baseline assessments were completed, followed by random assignment. Doses of pregabalin and placebo were increased over 4 weeks. The primary end point was treatment response, defined as a reduction of ≥ 2 points in worst pain by week 4, accompanied by a stable or reduced opioid dose, compared with baseline. Secondary end points assessed average pain, interference of pain with activity, breakthrough pain, mood, quality of life, and adverse events.
Results
A total of 233 patients were randomly assigned: 117 to placebo and 116 to pregabalin. The most common cancers were prostate (n = 88; 38%), breast (n = 77; 33%), and lung (n = 42; 18%). In the pregabalin arm, 45 patients (38.8%) achieved the primary end point, compared with 47 (40.2%) in the placebo arm (adjusted odds ratio, 1.07; 95% CI, 0.63 to 1.81; P = .816). There were no statistically significant differences in average pain, pain interference, or quality of life between arms. There were differences in mood (P = .031) and breakthrough pain duration (P = .037) between arms. Outcomes were compared at 4 weeks.
Conclusion
Our findings do not support the role of pregabalin in patients with CIBP receiving radiotherapy. The role of pregabalin in CIBP with a clinical neuropathic pain component is unknown
The Outer Disks of Early-Type Galaxies. I. Surface-Brightness Profiles of Barred Galaxies
We present a study of 66 barred, early-type (S0-Sb) disk galaxies, focused on
the disk surface brightness profile outside the bar region and the nature of
Freeman Type I and II profiles, their origins, and their possible relation to
disk truncations. This paper discusses the data and their reduction, outlines
our classification system, and presents -band profiles and classifications
for all galaxies in the sample.
The profiles are derived from a variety of different sources, including the
Sloan Digital Sky Survey (Data Release 5). For about half of the galaxies, we
have profiles derived from more than one telescope; this allows us to check the
stability and repeatability of our profile extraction and classification. The
vast majority of the profiles are reliable down to levels of mu_R ~ 27 mag
arcsec^-2; in exceptional cases, we can trace profiles down to mu_R > 28. We
can typically follow disk profiles out to at least 1.5 times the traditional
optical radius R_25; for some galaxies, we find light extending to ~ 3 R_25.
We classify the profiles into three main groups: Type I (single-exponential),
Type II (down-bending), and Type III (up-bending). The frequencies of these
types are approximately 27%, 42%, and 24%, respectively, plus another 6% which
are combinations of Types II and III. We further classify Type II profiles by
where the break falls in relation to the bar length, and in terms of the
postulated mechanisms for breaks at large radii ("classical trunction" of star
formation versus the influence of the Outer Lindblad Resonance of the bar). We
also classify the Type III profiles by the probable morphology of the outer
light (disk or spheroid). Illustrations are given for all cases. (Abridged)Comment: 41 pages, 26 PDF figures. To appear in the Astronomical Journal.
Version with full-resolution figures available at
http://www.mpe.mpg.de/~erwin/research
Entanglement-enhanced probing of a delicate material system
Quantum metrology uses entanglement and other quantum effects to improve the
sensitivity of demanding measurements. Probing of delicate systems demands high
sensitivity from limited probe energy and has motivated the field's key
benchmark-the standard quantum limit. Here we report the first
entanglement-enhanced measurement of a delicate material system. We
non-destructively probe an atomic spin ensemble by means of near-resonant
Faraday rotation, a measurement that is limited by probe-induced scattering in
quantum-memory and spin-squeezing applications. We use narrowband,
atom-resonant NOON states to beat the standard quantum limit of sensitivity by
more than five standard deviations, both on a per-photon and per-damage basis.
This demonstrates quantum enhancement with fully realistic loss and noise,
including variable-loss effects. The experiment opens the way to ultra-gentle
probing of single atoms, single molecules, quantum gases and living cells.Comment: 7 pages, 8 figures; Nature Photonics, advance online publication, 16
December 201
- …